Forbes October 10, 2024
Cytovale has developed a FDA-cleared, rapid diagnostic tool for sepsis, and it just raised $100 million to roll it out to hospital systems across the country.
Every year, over 1.7 million Americans will experience sepsis, which occurs when the immune system is unable to fight off an infection and instead begins an extreme response where it, in the words of Cytovale CEO Ajay Shah, starts “carpet bombing everything” and attacking the body’s own organs. But there hasn’t been a good way for doctors to quickly figure out what’s happening.
Shah’s company has developed the first rapid lab test for sepsis that’s been cleared by the FDA, called IntelliSep. The technology is already in place in six hospitals in two health...
Today's Sponsors
Today's Sponsor